Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study

Sanmartí Sala, RaimonInciarte-Mundo, JoseEstrada-Alarcon, PaulaGarcia-Manrique, MariaNarváez García, Francisco JavierRodríguez Moreno, JesúsGomez-Centeno, AntoniPascal i Capdevila, MarionaYagüe, Jordi2017-05-032017-05-032015-080003-4967https://hdl.handle.net/2445/110383Article en format correspondènciaWe read with great interest the paper by Chen et al1 analysing the relationship between therapeutic response to adalimumab and etanercept and serum drug trough levels in 70 patients with rheumatoid arthritis (RA). ...1 p.application/pdfeng(c) BMJ Publishing Group, 2015Artritis reumatoideMedicamentsAdministració de medicamentsSistema immunològicAnticossos monoclonalsRheumatoid arthritisDrugsAdministration of drugsImmune systemMonoclonal antibodiesTowards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR studyinfo:eu-repo/semantics/article6578952017-05-03info:eu-repo/semantics/openAccess